In this study, we demonstrated that the combination treatment of TAS‐102 and panitumumab exerted significant anticancer activity compared to that achieved by single‐agent treatment in in vitro and in vivo wild‐type KRAS colon cancer models. This evidence concerns the gene KRAS and malignant colon neoplasm.